RedHill Biopharma (RDHL) Amortization (2011 - 2025)

RedHill Biopharma (RDHL) has 15 years of Amortization data on file, last reported at $19.2 million in Q4 2025.

• Amortization for Q4 2025 came in at $19.2 million, down 13.51% year-over-year; the trailing twelve-month figure through Dec 2025 was $19.2 million (down 13.51% YoY), and the FY2025 annual result was $19.2 million, down 13.51% from the prior year.
• Amortization slipped to $19.2 million in Q4 2025 per RDHL's latest filing, from $22.3 million in the prior quarter.
• Over five years, Amortization peaked at $193.5 million in Q3 2022 and troughed at -$2.9 million in Q4 2022.
• A 5-year average of $51.1 million and a median of $22.2 million in 2024 frame the typical range for Amortization.
• On a YoY basis, Amortization climbed as much as 3471.98% in 2022 and fell as far as 121.36% in 2022.
• A 5-year view of Amortization shows it stood at $13.7 million in 2021, then tumbled by 121.36% to -$2.9 million in 2022, then jumped by 780.62% to $20.0 million in 2023, then gained by 11.21% to $22.2 million in 2024, then dropped by 13.51% to $19.2 million in 2025.
• Business Quant data shows RDHL's Amortization at $19.2 million in Q4 2025, $22.3 million in Q2 2025, and $22.2 million in Q4 2024.